Loading provider…
Loading provider…
Infectious Disease Physician in Hackensack, NJ
NPI: 1063489243Primary Practice Location
HACKENSACK UNIVERSITY MEDICAL CENTER
30 Prospect Ave, Hackensack, NJ
Primary Employer
Hmhmg Specialty Care
hmhn.org
HQ Phone
Get M.D. Bindu's Phone NumberMobile
Get M.D. Bindu's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNJ State Medical License
Muhlenberg Regional Medical Center
Residency • Internal Medicine
1995 - 1998
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 186 | 373 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 164 | 339 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 121 | 132 |
| 4 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 99 | 110 |
| 5 | 99221Initial hospital inpatient care, typically 30 minutes per day | 77 | 78 |
Authors: Martin Gutierrez, Sukhdeep Kaur, Andrew Ip, Michele Donato, Ming Tan, Samit Desai, Steven Park, Noa Biran, Rani Sebti, Tatyana Feldman, Lori Leslie, Andre Goy, Sarah Timmapuri, Sean Sadikot, Steven Sperber, Ronaldo Go, Stuart Goldberg, Scott Rowley, Cristina Cicogna, Alfred Gillio
Journal: JCI Insight
Publication Date: 2021-03-22
A US-Based Multi-Site Pilot to Screen Hepatitis B Surface Antigen-Positive Patients for Hepatitis D.
Authors: Nancy Glick, Su Wang, Madhu Suryadevara, Chinwe Ogedegbe
Journal: J Viral Hepat
Lead Sponsor: Daniel Benjamin
Collaborators: National Center for Advancing Translational Sciences (NCATS), Biomedical Advanced Research and Development Authority
Intervention / Treatment: DRUG: Infliximab, DRUG: Remdesivir, DRUG: Abatacept, DRUG: cenicriviroc (closed to enrollment as of 3-Sep-2021)